| scholarly article | Q13442814 |
| P2093 | author name string | Vineet Bhandari | |
| P2860 | cites work | NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. | Q37827272 |
| The potential of non-invasive ventilation to decrease BPD. | Q38098720 | ||
| Epidemiology of bronchopulmonary dysplasia | Q38196792 | ||
| A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia | Q42148858 | ||
| Familial and genetic susceptibility to major neonatal morbidities in preterm twins | Q42687167 | ||
| Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups | Q43238545 | ||
| Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. | Q44530206 | ||
| Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia. | Q48196450 | ||
| Respiratory morbidity, healthcare utilisation and cost of care at school age related to home oxygen status. | Q51733452 | ||
| Use of inhaled nitric oxide in preterm infants. | Q54384178 | ||
| A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia | Q82285581 | ||
| Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993-2006 | Q84579553 | ||
| Predictors of bronchopulmonary dysplasia | Q26829843 | ||
| MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations | Q27678661 | ||
| Caffeine Therapy for Apnea of Prematurity | Q29395883 | ||
| Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. | Q30544045 | ||
| Nebulized PPARγ agonists: a novel approach to augment neonatal lung maturation and injury repair in rats | Q33594612 | ||
| Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia | Q33622213 | ||
| Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases | Q33956836 | ||
| A potential role of the JNK pathway in hyperoxia-induced cell death, myofibroblast transdifferentiation and TGF-β1-mediated injury in the developing murine lung | Q34102085 | ||
| Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity | Q34247861 | ||
| The chitinase-like proteins breast regression protein-39 and YKL-40 regulate hyperoxia-induced acute lung injury. | Q34269049 | ||
| A critical regulatory role for macrophage migration inhibitory factor in hyperoxia-induced injury in the developing murine lung | Q34699934 | ||
| Long-term effects of caffeine therapy for apnea of prematurity | Q34711652 | ||
| Health care utilization by preterm infants with respiratory complications in Quebec | Q36138592 | ||
| Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth | Q36178195 | ||
| Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. | Q36244610 | ||
| Pulmonary outcomes in bronchopulmonary dysplasia | Q36543492 | ||
| Neurodevelopmental outcome of bronchopulmonary dysplasia | Q36543497 | ||
| Cost of morbidities in very low birth weight infants | Q36645155 | ||
| Small molecular modulation of macrophage migration inhibitory factor in the hyperoxia-induced mouse model of bronchopulmonary dysplasia | Q36797421 | ||
| Exploiting the PTHrP signaling pathway to treat chronic lung disease. | Q36921271 | ||
| Hyperoxia and interferon-γ-induced injury in developing lungs occur via cyclooxygenase-2 and the endoplasmic reticulum stress-dependent pathway | Q37056431 | ||
| Hyperoxia exacerbates postnatal inflammation-induced lung injury in neonatal BRP-39 null mutant mice promoting the M1 macrophage phenotype. | Q37375204 | ||
| Pitfalls, problems, and progress in bronchopulmonary dysplasia | Q37502269 | ||
| Caffeine induces alveolar apoptosis in the hyperoxia-exposed developing mouse lung | Q37619613 | ||
| Association of a vascular endothelial growth factor polymorphism with the development of bronchopulmonary dysplasia in Japanese premature newborns | Q37660950 | ||
| P921 | main subject | bronchopulmonary dysplasia | Q922640 |
| P304 | page(s) | 76 | |
| P577 | publication date | 2014-07-25 | |
| P1433 | published in | Frontiers in pediatrics | Q27725038 |
| P1476 | title | Drug therapy trials for the prevention of bronchopulmonary dysplasia: current and future targets | |
| P478 | volume | 2 |
| Q26795723 | Affect of Early Life Oxygen Exposure on Proper Lung Development and Response to Respiratory Viral Infections |
| Q46169553 | Alveolar formation is dysregulated by restricted nutrition but not excess sedation in preterm lambs managed by noninvasive support. |
| Q34726840 | Animal models of bronchopulmonary dysplasia. The term mouse models |
| Q91272493 | Factors associated with development of early and late pulmonary hypertension in preterm infants with bronchopulmonary dysplasia |
| Q42611894 | Hyperoxia causes miR-34a-mediated injury via angiopoietin-1 in neonatal lungs |
| Q89745177 | Is bronchopulmonary dysplasia decided before birth? |
Search more.